Funding for this research was provided by:
University Hospital Foundation (Pro00069595)
Received: 9 April 2021
Accepted: 18 October 2021
First Online: 8 November 2021
: The research protocol was reviewed and approved by the Health Research Ethics Board of the University of Alberta (approval number Pro00069595). Written, informed consent to participate will be obtained from all participants. Please see Additional file InternalRef removed for ethics approval documents and consent forms.
: Not applicable
: P. Smyth has received grant support through CIHR and the MS Society of Canada and is a co-investigator in a study funded by an unrestricted research grant from Biogen pharmaceuticals. She has consulted on advisory boards for Novartis Pharmaceuticals, Roche Canada, Biogen Idec Pharmaceuticals, Alexion Pharmaceuticals, Alberta Blue Cross and the Short Term Exceptional Drug Therapy Program for Alberta Health Services.K. Watson has no conflicts of interest to declareR. Tsuyuki has done consulting for Emergent BioSolutions, Shoppers Drug Mart and has received investigator-initiated research grants from Sanofi, Merck, AstraZeneca, and Pfizer.